Strides Pharma Science Ltd · NSE:STAR

Strides Pharma Science — Q4 FY2022 Earnings Presentation

18 slides from Strides Pharma Science's earnings presentation, May 24, 2022

  1. Slide 1: Strides announces Q4FY22 & FY22 results

    Strides announces Q4FY22 & FY22 results ▸ Reports improved growth in Q4 with a modest EBITDA pick up ▸ Guides for an encouraging FY23 outlook Q4 and FY22 Earnings Update | May 24, 2022

  2. Slide 2: Strides reports an improved Q4FY22 after nine months of tepid performance

    Strides reports an improved Q4FY22 after nine months of tepid performance Quarterly Performance (₹m) Particulars Q4 FY22 Q3 FY22 Q4 FY21 QoQ YoY FY22 has been a challenging year for the pharma industry and, particularly Revenues 8,699 7,968 9,115 9% ▲ -5%▼ for Strides, given the significant headwind

  3. Slide 3: Key changes in management team

    Key changes in management team The Evolving global Given the challenging business environment post-Covid and for Strides in particular, we have made several environment & management and operational changes to adapt to the evolving environment strategic priorities ◎ Arun Kumar has returned to the Com

  4. Slide 4: Our businesses have witnessed green shoots with modest EBITDA pickup

    Our businesses have witnessed green shoots with modest EBITDA pickup & we will build strongly from here Quarterly Performance (₹m) Particulars Q4 FY22 Q3 FY22 Q4 FY21 QoQ YoY ◎ Revenues at ₹3,301m ($44m) for Q4FY22, up from ₹2,831m ($38m) in Q3FY22; US US returns to contributed 38% of consolidated r

  5. Slide 5: FY22 has been a difficult year with lowest ever EBITDA performance

    FY22 has been a difficult year with Strides reporting its lowest ever EBITDA performance ◎ Significant fall in US revenues due to covid-related headwinds leading to drop in volumes and margin compression due to the heightened competitive intensity and higher channel inventory. Challenging business ◎

  6. Slide 6: Strides guides for an encouraging FY23 with focus on growth, higher cashflows & reduction in debt

    Strides guides for an encouraging FY23 with focus on growth, higher cashflows & reduction in debt Growth Cost Improvement Plan (CIPs) Debt Reduction target of ~ ₹10bn in FY23 Bounce back in the US markets led by new product A significant reduction in investments in R&D for the US, Target to reduce t

  7. Slide 7: FY22 Highlights and FY23 Outlook

    FY22 Highlights and FY23 Outlook *Please refers to investor deck on Stelis for update on biotech business

  8. Slide 8: US business will linearly grow to $250m+ in FY23

    While the market remains competitive, the US business for Strides will linearly grow to $250m+ in FY23 US Revenues - Quarterly Trend ($m) Business updates • Revenues from the US for Q4FY22 stood at ₹3,301 ($44m), up 17% QoQ, Significant price representing 38% of consolidated revenues for Q4FY22. ero

  9. Slide 9: Pivots in place to deliver sustainable growth for the US

    US will continue to be a focus market for Strides with growth driven by portfolio ◦ The business environment is constantly evolving post-Covid, with select products recouping both volume and price while several other products continue to face price intensity and lower volume pick up. Business ◦ Most

  10. Slide 10: ORM delivers its best quarterly performance with Q4FY22 revenues at $42m

    ORMs delivers its best quarterly performance with Q4FY22 revenues at $42m ORM Revenues - Quarterly Trend ($m) Business updates Covid related • Revenues from the ORM for Q4FY22 stood at ₹3,133m ($42m), up 5% QoQ and up supply 15% YoY, representing 36% of consolidated revenues for Q4FY22. disruptions

  11. Slide 11: Emerging and access markets business delivers 22% YoY growth in FY22

    Emerging and access markets business delivers a robust 22% YoY growth in FY22 EM Revenues - Quarterly Trend ($m) Business updates • Revenues from emerging markets for Q4FY22 stood at ₹2,265m ($30m), up 5% QoQ and up 7% YoY. 29 29 30 28 23 • Emerging markets revenues for FY 22 at ₹8,116 ($109m) repre

  12. Slide 12: Aggressive focus in FY23 on optimizing operating costs

    Besides targeting growth, our aggressive focus in FY23 will be on optimizing operating costs ◦ Optimization of R&D investment for the US as we unlock ◦ Alternate Vendor Development (AVD) programs to drive value from the large basket of approved products cost optimization and supply continuity ◦ R&D

  13. Slide 13: Focus on free cash generation and balance sheet initiatives for debt reduction in FY23

    Focus on free cash generation and balance sheet initiatives for significant debt reduction in FY23 FY22 Debt book FY23 Outlook Particulars Value Targeted Gross debt reduction by end of FY23 in ₹ m Gross Debt for Strides 27,920 ~ ₹10bn H1 FY23 H2 FY23 FY23 Less: Deferred Consideration receivable -5,7

  14. Slide 14: Financial Performance: Q4FY22 and FY22

    Financial Performance: Q4FY22 and FY22

  15. Slide 15: Key P&L Highlights – Q4 and FY22

    Key P&L Highlights – Q4 and FY22 Income statement (₹m) Particulars Q4 FY22 Q3 FY22 Q4 FY21 QoQ YoY FY22 FY21 YoY Revenues 8,699 7,968 9,115 9% -5% 30,946 33,308 -7% EBITDA 461 40 1,602 100%+ -71% 43 6,497 -99% EBITDA % 5.3% 0.5% 17.6% 0.1% 19.5% Reconciliation of EBITDA (₹m) As per SEBI results Q4 F

  16. Slide 16: Details on Non-operational items in Q4 and FY22

    Details on Non-operational items in Q4 and FY22 One off gains in P&L for Q4 and FY22 Particulars Description Q4 FY22 FY22 Current Tax (Refunds) Tax refund on account of certain tax credits for earlier years 1,605 1,605 Other Income Interest income on Tax on the said refund recorded as part of other

  17. Slide 17: Q4 and FY22 Earnings Call invitation

    Strides Pharma Science Ltd – Q4 and FY22 Earnings Call invites you to interact with the senior management on Q4 and FY22 Pre-register and join without operator CLICK HERE Wednesday, 25th May 2022 8:30am IST / 04:00am BST / 11:00pm EDT / 11:00am HKT Join through an operator using dial in numbers Indi

  18. Slide 18: Thank You

    THANK YOU Strides Pharma Science Limited CIN: L24230MH1990PLC057062 REGISTERED OFFICE 201, Devavrata, Sector 17, Vashi, Navi Mumbai - 400 703, India Tel.: +91 22 2789 2924/2789 3199 Email: corpcomm@strides.com Website: www.strides.com CIN: L24230MH1990PLC057062 CORPORATE OFFICE Bannerghatta Road, Be

Strides Pharma Science — Q4 FY2022 Earnings Presentation on 6ix